NASDAQ$PLSE
Pulse Biosciences Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Pulse Biosciences reported financial results for Q1 2024 and provided business updates.
Pulse Biosciences reported a GAAP net loss of $10.1 million for the first quarter of 2024, compared to a $9.8 million loss in the same period last year. Cash and cash equivalents totaled $34.9 million as of March 31, 2024. The company is focused on advancing its CellFX nsPFA technology and executing its percutaneous electrode pilot program.
- Total GAAP costs and expenses were $10.6 million, driven by an increase in non-cash stock-based compensation expense.
- Non-GAAP costs and expenses were $8.6 million.
- GAAP net loss was $10.1 million, while non-GAAP net loss was $8.1 million.
- Cash and cash equivalents totaled $34.9 million as of March 31, 2024.
Headline financials
Revenue & EPS history
Pulse Biosciences · Revenue · Quarterly
$0
Forward guidance
Pulse Biosciences is focused on executing its CellFX nsPFA percutaneous electrode pilot program to initiate the commercial launch and continuing to advance the clinical and regulatory work with its CellFX nsPFA Surgical Clamp and 360° Cardiac Catheter.
Tailwinds
- FDA clearance of the CellFX nsPFA Percutaneous Electrode System
- Posters, abstracts and a live case highlighting the CellFX nsPFA 360° Cardiac Catheter at HRS next week
- Focus on delivering the benefits of CellFX nsPFA to patients and providers following further clinical evaluations and regulatory clearances.
- Executing CellFX nsPFA percutaneous electrode pilot program to initiate the commercial launch
- Continuing to advance the clinical and regulatory work with our CellFX nsPFA Surgical Clamp and 360° Cardiac Catheter
Headwinds
- Need for further clinical evaluations
- Need for regulatory clearances
- Cash used in the first quarter of 2024 was $9.5 million compared to $7.2 million in the same period in the prior year
- GAAP net loss for the three months ended March 31, 2024 was ($10.1) million compared to ($9.8) million for the three months ended March 31, 2023
- The remaining increase in costs and expenses compared to the prior year was driven by an increase in research and development expenses to support the development of the CellFX nsPFA product portfolio.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
-0.0%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+9.3%
Avg return
30 days after
49%
19 / 39 earnings
Positive
+33.9%
Q4 2022
Best reaction
-36.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.6% | -4.6% | +34.5% | |
| Q4 2025 | -14.4% | -23.4% | -11.9% | |
| Q3 2025 | -1.2% | -6.1% | -20.0% | |
| Q1 2025 | +1.4% | -3.3% | +1.5% | |
| Q4 2024 | +6.0% | +6.8% | +14.4% | |
| Q3 2024 | +2.3% | -10.9% | +25.6% | |
| Q2 2024 | +8.1% | +21.5% | +9.5% | |
| Q1 2024 | -10.7% | -3.6% | +88.2% | |
| Q4 2023 | -4.9% | -8.5% | -14.4% | |
| Q3 2023 | +12.8% | +18.6% | +95.5% | |
| Q2 2023 | -0.4% | +9.2% | -35.3% | |
| Q1 2023 | -2.5% | -4.6% | -16.0% | |
| Q4 2022 | +33.9% | +57.4% | +156.6% | |
| Q3 2022 | +10.9% | +12.5% | +57.1% | |
| Q2 2022 | +8.7% | +10.6% | +1.2% | |
| Q1 2022 | -36.5% | -7.7% | -3.9% | |
| Q4 2021 | -28.4% | -25.0% | -49.6% | |
| Q3 2021 | -0.2% | -1.5% | -21.4% | |
| Q2 2021 | +7.9% | -2.1% | +2.1% | |
| Q1 2021 | +4.8% | +1.7% | +3.6% | |
| Q4 2020 | -9.2% | -17.5% | -35.1% | |
| Q3 2020 | +15.9% | +22.3% | +40.5% | |
| Q2 2020 | -6.4% | -6.1% | -15.0% | |
| Q1 2020 | +18.8% | -1.7% | -27.2% | |
| Q4 2019 | +21.1% | +5.2% | +14.6% | |
| Q3 2019 | -3.5% | -2.8% | -1.7% | |
| Q2 2019 | -2.5% | +4.6% | +16.1% | |
| Q1 2019 | -32.5% | -22.1% | -26.8% | |
| Q4 2018 | +4.0% | +11.3% | +9.4% | |
| Q3 2018 | +22.7% | +32.7% | +17.3% | |
| Q2 2018 | -0.9% | -6.7% | +4.1% | |
| Q1 2018 | -14.7% | -25.1% | -12.4% | |
| Q4 2017 | +0.1% | +1.8% | +38.5% | |
| Q3 2017 | +9.1% | +18.0% | -11.0% | |
| Q2 2017 | -16.6% | -11.6% | -25.2% | |
| Q1 2017 | -9.5% | -14.7% | +24.9% | |
| Q4 2016 | +6.4% | +18.7% | +12.7% | |
| Q3 2016 | +0.0% | -0.7% | -10.6% | |
| Q2 2016 | +1.5% | +2.2% | +31.3% | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro